Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28379714 | 0.85 | PDE3A (0.47) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL1939478 | 0.85 | PDE3A (0.47) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL7794942 | 0.84 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL992472 | 0.84 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL3038818 | 0.84 | PDE3A (0.52) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL51650 | 0.84 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL4971926 | 0.84 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL3449198 | 0.84 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL27544566 | 0.84 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL2118776 | 0.83 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790374-B2 | Process for sequence saturation mutagenesis (SeSaM) | BASF AKTIENGESELLSCHAFT (DE) | 2010-09-07 | — | — | US | claimed |
| EP-1670914-B1 | A PROCESS FOR SEQUENCE SATURATION MUTAGENESIS (SESAM) | BASF AG (DE) | 2008-01-23 | — | — | EP | claimed |
| EP-1812456-A2 | ß-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2007-08-01 | — | — | EP | claimed |
| US-20060223148-A1 | Process for sequence saturation mutagenesis (sesam) | BASF AKTIENGESCHAFT (DE) | 2006-10-05 | — | — | US | claimed |
| EP-1670914-A1 | A PROCESS FOR SEQUENCE SATURATION MUTAGENESIS (SESAM) | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2006045616-A2 | β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2006-05-04 | — | — | WO | claimed |
| WO-2005035757-A1 | A PROCESS FOR SEQUENCE SATURATION MUTAGENESIS (SESAM) | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | WO | claimed |
| US-20260125669-A1 | METHODS AND COMPOSITIONS FOR SYNTHETIC EVOLUTION | UNIVERSITAT POMPEU FABRA (ES) | 2026-05-07 | — | — | US | disclosed |
| EP-4599047-A1 | METHODS AND COMPOSITIONS FOR SYNTHETIC EVOLUTION | Universitat Pompeu Fabra (ES) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024074709-A1 | METHODS AND COMPOSITIONS FOR SYNTHETIC EVOLUTION | UNIVERSITAT POMPEU FABRA (ES) | 2024-04-11 | — | — | WO | disclosed |
| US-7790374-B2 | Process for sequence saturation mutagenesis (SeSaM) | BASF AKTIENGESELLSCHAFT (DE) | 2010-09-07 | — | — | US | disclosed |
| EP-1670914-B1 | A PROCESS FOR SEQUENCE SATURATION MUTAGENESIS (SESAM) | BASF AG (DE) | 2008-01-23 | — | — | EP | disclosed |
| US-20060223148-A1 | Process for sequence saturation mutagenesis (sesam) | BASF AKTIENGESCHAFT (DE) | 2006-10-05 | — | — | US | disclosed |
| EP-1670914-A1 | A PROCESS FOR SEQUENCE SATURATION MUTAGENESIS (SESAM) | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005035757-A1 | A PROCESS FOR SEQUENCE SATURATION MUTAGENESIS (SESAM) | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125669-A1 | METHODS AND COMPOSITIONS FOR SYNTHETIC EVOLUTION | POLM, CPSF6, CPSF1 | PDE3A 4739/4885PDE4D 4481/4885SLC29A1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.